[Hand-foot syndrome: A new side effect of erlotinib].
BACKGROUND
Erlotinib (Tarceva) belongs to the family of epidermal growth receptor factor (EGFR) inhibitors. Used in the treatment of some cancers, it is responsible for several cutaneous side effects. We report a case of hand-foot syndrome, which has not previously been described with this drug to our knowledge.


METHODS
A 65-year-old patient was given erlotinib for lung cancer and after the first month of treatment, he developed severe hand-foot syndrome.


CONCLUSIONS
Hand-foot syndrome consists of abrupt bilateral and painful acral erythema associated with dysesthesia. It is a dose-dependent side effect of certain cytostatic drugs. It may sometimes require withdrawal of the causative drug. Care must be taken to identify the early signs of hand-foot syndrome in patients treated with erlotinib.
Rouxel
A-M
AM
Service de dermatologie, CHU Morvan de Brest, 2, avenue Foch, 29200 Brest, France. rouxel.annemarie@free.fr
Roguedas
A-M
AM
Descourt
R
R
Misery
L
L
D000368:Aged; D003937:Diagnosis, Differential; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D004890:Erythema / Q000139:chemically induced*; D005533:Foot Dermatoses / Q000139:chemically induced*; D005534:Foot Diseases / Q000139:chemically induced*; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000633:toxicity; D011799:Quinazolines / Q000633:toxicity*; D013577:Syndrome
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors